title: Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
abstract: OBJECTIVE
  To describe the ocular effects associated with the administration of the systemic epidermal growth factor receptor (EGFR) inhibitors panitumumab and erlotinib.
  
  
  METHODS
  Retrospective, noncomparative interventional case series.
  
  
  METHODS
  Ten eyes of 5 patients in treatment with systemic EGFR inhibitors, 4 patients with erlotinib for end-stage lung carcinoma, and 1 patient with panitumumab for end-stage colorectal cancer.
  
  
  METHODS
  Data collected from charts included gender, age at presentation, systemic disease, and clinical presentation in each eye.
  
  
  METHODS
  Demographics on presentation and clinical findings.
  
  
  RESULTS
  Multiple epithelial defects were observed in all 10 eyes, corneal melting and thinning were observed in 3 eyes of 2 patients, 2 eyes of 1 patient presented with lower lid ectropion, and 2 eyes of 2 patients presented with corneal perforation, both requiring a penetrating keratoplasty.
  
  
  CONCLUSIONS
  Severe ocular side effects, including corneal perforation, may be associated with the use of the EGFR inhibitors panitumumab and erlotinib.
authors.affiliation: Department of Ophthalmology, Hospital Clinic of Barcelona, Spain.
authors.forename: Alejandro
authors.initials: A
authors.lastname: Saint-Jean
authors.forename: Maite
authors.initials: M
authors.lastname: Sainz de la Maza
authors.forename: Merce
authors.initials: M
authors.lastname: Morral
authors.forename: Josep
authors.initials: J
authors.lastname: Torras
authors.forename: Ramon
authors.initials: R
authors.lastname: Quintana
authors.forename: Juan Jose
authors.initials: JJ
authors.lastname: Molina
authors.forename: Nicolas
authors.initials: N
authors.lastname: Molina-Prat
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D057112:Corneal Perforation / Q000139:chemically induced* / Q000175:diagnosis / Q000601:surgery; D004483:Ectropion / Q000139:chemically induced* / Q000175:diagnosis; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D015948:Keratoplasty, Penetrating; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000077544:Panitumumab; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D012189:Retrospective Studies; D014792:Visual Acuity
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors